The pharmacy benefits landscape may be shifting with the new Federal Trade Commission appointee Alvaro Bedoya. He should be the tie-breaker in the 2-2 gridlock that has plagued the commission. One of the stymied issues has been whether the FTC should move forward in its investigation into the cost of insulin.